All In Biotech

NDA 021906 · Abbvie

Kaletra

Lopinavir, Ritonavir · Oral · Cytochrome P450 3A Inhibitor; Protease Inhibitor

Priority review

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2005

Oct 28, 2005

Approved uses

7

Original approval plus efficacy supplements

Registered trials

372

120 Phase 3, 10 recruiting

FAERS reports

13,489

12,415 serious, 1,781 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • KALETRA · LOPINAVIR 100MG; RITONAVIR 25MG · TABLET, ORAL · Prescription · TE AB
  • KALETRA · LOPINAVIR 200MG; RITONAVIR 50MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lopinavir" as an intervention, any sponsor and status, largest first.

All 372 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug interaction1,338
  • depression1,141
  • nausea791
  • drug exposure during pregnancy778
  • diarrhoea774
  • foetal exposure during pregnancy757
  • anxiety712
  • vomiting712
  • off label use695
  • pain692
  • emotional distress578
  • renal failure540

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004761
2005608
2006677
2007725
2008999
20091,056
2010922
2011628
2012681
2013469
2014576
2015587
2016407
2017268
2018312
2019427
20201,446
2021862
2022473
2023217
2024137
2025177
202669

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kaletra (Lopinavir/Ritonavir)

2024 spending

$295K

Beneficiaries

52

262 claims

Per beneficiary

$5,668

$7.96 per unit

View as table
YearSpending
2020$14,556,207
2021$9,065,449
2022$2,288,398
2023$497,757
2024$294,717

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 754 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.